Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
An examination of short-term operating activity ratios reveals several noteworthy trends between 2021 and 2025. Generally, the company demonstrates efficient management of its short-term assets and liabilities, though some indicators suggest a potential shift in operational dynamics towards the end of the period.
- Inventory Management
- Inventory turnover exhibited an increasing trend from 3.88 in 2021 to 5.06 in 2023, indicating improved efficiency in converting inventory into sales. This positive trend plateaued in 2024 and experienced a slight decline to 4.85 in 2025. Correspondingly, the average inventory processing period decreased from 94 days in 2021 to 72 days in 2023, before stabilizing at 72 days in 2024 and increasing slightly to 75 days in 2025. These figures suggest a generally effective inventory management system, with a possible slight slowdown in inventory conversion towards the end of the analyzed period.
- Receivables Management
- Receivables turnover increased from 4.92 in 2021 to 5.53 in 2022, demonstrating improved efficiency in collecting receivables. While the ratio decreased slightly to 5.21 in 2023 and remained relatively stable at 5.23 in 2024, it experienced a further decline to 5.01 in 2025. The average receivable collection period decreased from 74 days in 2021 to 66 days in 2022, remaining at 70 days for 2023 and 2024, and then increasing to 73 days in 2025. This suggests a lengthening in the time taken to collect receivables in the most recent year.
- Payables Management
- Payables turnover consistently increased from 6.83 in 2021 to 8.97 in 2023, indicating the company was becoming more efficient in paying its suppliers. However, this trend reversed in 2024, with the ratio decreasing to 8.18, and continued to decline to 7.27 in 2025. The average payables payment period decreased from 53 days in 2021 to 41 days in 2023, then increased to 45 days in 2024 and 50 days in 2025. This suggests the company is taking longer to pay its suppliers in recent periods.
- Overall Operating Cycle & Cash Conversion
- The operating cycle decreased from 168 days in 2021 to 142 days in 2023, indicating a faster overall conversion of investments in inventory and receivables into cash. It then increased to 148 days in 2025. The cash conversion cycle followed a similar pattern, decreasing from 115 days in 2021 to 97 days in 2023, before stabilizing at 98 days in 2025. The slight increases in both cycles in 2025 warrant further investigation.
- Working Capital Turnover
- Working capital turnover decreased from 5.87 in 2021 to 3.30 in 2025. This indicates a declining efficiency in utilizing working capital to generate sales. The most significant decrease occurred between 2022 and 2023, suggesting a substantial change in working capital management or sales levels during that period.
In summary, while the company initially demonstrated improvements in its operating efficiency, several ratios indicate a potential shift in trends towards the end of the analyzed period. The increases in inventory processing and receivable collection periods, coupled with the decrease in payables turnover and working capital turnover, suggest a need for further analysis to understand the underlying causes and potential implications for future performance.
AI Ask an analyst for more
Turnover Ratios
Average No. Days
Inventory Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of revenues | 26,318) | 25,177) | 25,757) | 25,944) | 19,573) | |
| Inventories | 5,425) | 4,978) | 5,088) | 5,634) | 5,051) | |
| Short-term Activity Ratio | ||||||
| Inventory turnover1 | 4.85 | 5.06 | 5.06 | 4.60 | 3.88 | |
| Benchmarks | ||||||
| Inventory Turnover, Competitors2 | ||||||
| AbbVie Inc. | 3.68 | 4.04 | 4.98 | 4.87 | 5.58 | |
| Amgen Inc. | 1.93 | 1.84 | 0.89 | 1.30 | 1.58 | |
| Bristol-Myers Squibb Co. | 5.18 | 5.46 | 4.02 | 4.33 | 4.74 | |
| Danaher Corp. | 4.04 | 4.15 | 3.80 | 4.03 | 4.16 | |
| Eli Lilly & Co. | 0.80 | 1.11 | 1.23 | 1.54 | 1.88 | |
| Gilead Sciences Inc. | 3.51 | 3.66 | 3.64 | 3.75 | 4.08 | |
| Johnson & Johnson | 2.13 | 2.21 | 2.37 | 2.49 | 2.87 | |
| Merck & Co. Inc. | 2.46 | 2.49 | 2.54 | 2.95 | 2.29 | |
| Pfizer Inc. | 1.51 | 1.65 | 2.45 | 3.82 | 3.40 | |
| Regeneron Pharmaceuticals Inc. | 0.66 | 0.64 | 0.70 | 0.65 | 1.25 | |
| Vertex Pharmaceuticals Inc. | 0.98 | 1.27 | 1.71 | 2.35 | 2.56 | |
| Inventory Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 2.23 | 2.46 | 2.55 | 3.06 | 3.11 | |
| Inventory Turnover, Industry | ||||||
| Health Care | 7.55 | 7.56 | 7.36 | 7.85 | 7.90 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Inventory turnover = Cost of revenues ÷ Inventories
= 26,318 ÷ 5,425 = 4.85
2 Click competitor name to see calculations.
The inventory turnover ratio demonstrates an increasing trend from 2021 to 2023, followed by stabilization and a slight decrease. This suggests evolving efficiency in managing inventory levels relative to cost of revenues.
- Inventory Turnover Trend
- The inventory turnover ratio increased from 3.88 in 2021 to 4.60 in 2022, indicating improved efficiency in converting inventory into sales. This positive trend continued into 2023, reaching 5.06. The ratio remained stable at 5.06 in 2024 before decreasing slightly to 4.85 in 2025.
- Cost of Revenues
- Cost of revenues increased significantly from US$19,573 million in 2021 to US$25,944 million in 2022. Subsequent years show more moderate fluctuations, with a decrease to US$25,177 million in 2024 and a rise to US$26,318 million in 2025. This suggests a period of substantial growth followed by stabilization and a modest increase.
- Inventory Levels
- Inventories increased from US$5,051 million in 2021 to US$5,634 million in 2022, coinciding with the increase in cost of revenues. Inventory levels then decreased to US$5,088 million in 2023 and further to US$4,978 million in 2024. A slight increase to US$5,425 million is observed in 2025. The fluctuations in inventory levels appear to be managed in relation to the changes in cost of revenues, contributing to the observed turnover ratio trends.
The stabilization of the inventory turnover ratio in 2024, followed by a minor decline in 2025, warrants further investigation. While still at a relatively high level, the slight decrease could indicate a potential slowing of sales relative to inventory investment, or a strategic decision to increase inventory holdings. The concurrent increase in inventory value in 2025 supports the latter possibility.
AI Ask an analyst for more
Receivables Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenues | 44,556) | 42,879) | 42,857) | 44,915) | 39,211) | |
| Accounts receivable, less allowances | 8,900) | 8,191) | 8,221) | 8,115) | 7,977) | |
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | 5.01 | 5.23 | 5.21 | 5.53 | 4.92 | |
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 4.86 | 5.16 | 4.87 | 5.16 | 5.63 | |
| Amgen Inc. | 3.67 | 4.72 | 3.70 | 4.46 | 4.96 | |
| Bristol-Myers Squibb Co. | 4.87 | 5.19 | 4.93 | 5.48 | 5.65 | |
| Danaher Corp. | 6.28 | 6.75 | 6.09 | 6.40 | 6.36 | |
| Eli Lilly & Co. | 3.67 | 4.09 | 3.75 | 4.14 | 4.24 | |
| Gilead Sciences Inc. | 5.89 | 6.47 | 5.78 | 5.65 | 6.01 | |
| Johnson & Johnson | 5.48 | 5.98 | 5.73 | 5.88 | 6.14 | |
| Merck & Co. Inc. | 5.52 | 6.24 | 5.81 | 6.27 | 5.28 | |
| Pfizer Inc. | 5.27 | 5.55 | 5.33 | 9.24 | 7.16 | |
| Regeneron Pharmaceuticals Inc. | 2.50 | 2.29 | 2.31 | 2.28 | 2.66 | |
| Vertex Pharmaceuticals Inc. | 5.85 | 6.85 | 6.31 | 6.19 | 6.66 | |
| Receivables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.79 | 5.26 | 4.96 | 5.76 | 5.54 | |
| Receivables Turnover, Industry | ||||||
| Health Care | 7.58 | 7.97 | 7.66 | 8.22 | 8.00 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Receivables turnover = Revenues ÷ Accounts receivable, less allowances
= 44,556 ÷ 8,900 = 5.01
2 Click competitor name to see calculations.
The receivables turnover ratio exhibited a generally stable pattern over the five-year period, with some fluctuation. Revenues demonstrated an overall increasing trend, while accounts receivable remained relatively consistent before a notable increase in the final year. This interplay influenced the receivables turnover ratio’s behavior.
- Receivables Turnover Trend
- The receivables turnover ratio increased from 4.92 in 2021 to 5.53 in 2022, indicating improved efficiency in collecting receivables. A slight decrease to 5.21 was observed in 2023, followed by a further slight increase to 5.23 in 2024. The ratio concluded the period with a decrease to 5.01 in 2025.
- Revenue Impact
- Revenues increased from US$39,211 million in 2021 to US$44,915 million in 2022, contributing to the initial rise in the receivables turnover ratio. Revenue growth slowed in subsequent years, reaching US$42,857 million in 2023 and US$42,879 million in 2024, before increasing again to US$44,556 million in 2025. The slower revenue growth in 2023 and 2024 likely contributed to the stabilization of the receivables turnover ratio during those years.
- Accounts Receivable Impact
- Accounts receivable remained relatively stable between 2021 and 2024, fluctuating between US$7,977 million and US$8,221 million. However, a significant increase to US$8,900 million was recorded in 2025. This increase in accounts receivable, coupled with a modest increase in revenue, resulted in the decrease of the receivables turnover ratio in the final year of the period.
The observed trends suggest that the company generally maintained a consistent ability to convert receivables into cash. The increase in accounts receivable in 2025 warrants further investigation to determine if it represents a change in credit policy, slower collections, or other factors impacting the company’s working capital management.
AI Ask an analyst for more
Payables Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of revenues | 26,318) | 25,177) | 25,757) | 25,944) | 19,573) | |
| Accounts payable | 3,622) | 3,079) | 2,872) | 3,381) | 2,867) | |
| Short-term Activity Ratio | ||||||
| Payables turnover1 | 7.27 | 8.18 | 8.97 | 7.67 | 6.83 | |
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 5.07 | 5.74 | 5.54 | 5.94 | 6.05 | |
| Amgen Inc. | 5.09 | 6.74 | 5.32 | 4.08 | 4.72 | |
| Bristol-Myers Squibb Co. | 3.90 | 3.88 | 3.28 | 3.33 | 3.37 | |
| Danaher Corp. | 5.45 | 5.52 | 5.58 | 5.45 | 4.48 | |
| Eli Lilly & Co. | 2.05 | 2.61 | 2.73 | 3.43 | 4.38 | |
| Gilead Sciences Inc. | 8.72 | 7.50 | 11.81 | 6.25 | 9.36 | |
| Johnson & Johnson | 2.52 | 2.66 | 2.76 | 2.66 | 2.70 | |
| Merck & Co. Inc. | 3.72 | 3.72 | 4.11 | 4.08 | 2.96 | |
| Pfizer Inc. | 3.07 | 3.17 | 3.72 | 5.04 | 5.53 | |
| Regeneron Pharmaceuticals Inc. | 2.24 | 2.50 | 2.99 | 2.65 | 4.32 | |
| Vertex Pharmaceuticals Inc. | 3.58 | 3.71 | 3.46 | 3.55 | 4.64 | |
| Payables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 3.72 | 4.08 | 4.25 | 4.28 | 4.23 | |
| Payables Turnover, Industry | ||||||
| Health Care | 6.15 | 6.10 | 5.97 | 5.79 | 5.84 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Payables turnover = Cost of revenues ÷ Accounts payable
= 26,318 ÷ 3,622 = 7.27
2 Click competitor name to see calculations.
The accounts payable activity demonstrates a fluctuating pattern over the five-year period. While cost of revenues generally increased, the relationship with accounts payable and the resulting turnover ratio exhibited variability.
- Payables Turnover Trend
- The payables turnover ratio increased from 6.83 in 2021 to 7.67 in 2022, indicating a more efficient use of credit terms with suppliers. A further increase to 8.97 in 2023 suggests continued improvement in managing payments to suppliers. However, the ratio decreased to 8.18 in 2024, and then to 7.27 in 2025, signaling a potential slowing in the rate at which the company pays its suppliers.
The cost of revenues experienced growth throughout the period, rising from US$19,573 million in 2021 to US$26,318 million in 2025. Accounts payable also generally increased, moving from US$2,867 million in 2021 to US$3,622 million in 2025, though not consistently year-over-year. The increase in accounts payable did not keep pace with the growth in cost of revenues in the latter years, contributing to the decline in the payables turnover ratio.
- Accounts Payable Behavior
- Accounts payable increased from 2021 to 2022, then decreased in 2023. A slight increase occurred in 2024, followed by a more substantial increase in 2025. This suggests potential shifts in supplier relationships, negotiation strategies, or payment terms. The fluctuations in accounts payable, combined with the increasing cost of revenues, impacted the payables turnover ratio.
The decreasing payables turnover in 2024 and 2025 warrants further investigation. It could indicate the company is taking longer to pay its suppliers, potentially to manage cash flow, or it could reflect a change in purchasing practices. Alternatively, it could be a result of increased supplier credit terms.
AI Ask an analyst for more
Working Capital Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | 28,707) | 22,137) | 24,589) | 25,229) | 20,113) | |
| Less: Current liabilities | 15,189) | 13,332) | 14,012) | 17,010) | 13,436) | |
| Working capital | 13,518) | 8,805) | 10,577) | 8,219) | 6,677) | |
| Revenues | 44,556) | 42,879) | 42,857) | 44,915) | 39,211) | |
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | 3.30 | 4.87 | 4.05 | 5.46 | 5.87 | |
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | 9.85 | 5.40 | 2.25 | 3.82 | 3.37 | |
| Bristol-Myers Squibb Co. | 7.83 | 7.79 | 4.60 | 8.30 | 3.95 | |
| Danaher Corp. | 4.13 | 8.85 | 4.22 | 4.20 | 8.40 | |
| Eli Lilly & Co. | 3.19 | 10.32 | — | 31.84 | 8.33 | |
| Gilead Sciences Inc. | 4.43 | 3.99 | 5.61 | 8.42 | 8.54 | |
| Johnson & Johnson | 62.88 | 15.94 | 11.81 | — | 5.95 | |
| Merck & Co. Inc. | 4.28 | 6.19 | 9.29 | 5.16 | 7.62 | |
| Pfizer Inc. | 10.58 | 8.64 | — | 11.09 | 4.83 | |
| Regeneron Pharmaceuticals Inc. | 1.05 | 0.97 | 0.82 | 0.96 | 1.59 | |
| Vertex Pharmaceuticals Inc. | 1.64 | 1.83 | 0.93 | 0.85 | 1.02 | |
| Working Capital Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 6.50 | 7.86 | 6.68 | 7.25 | 5.87 | |
| Working Capital Turnover, Industry | ||||||
| Health Care | 11.25 | 12.35 | 10.99 | 11.30 | 8.57 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Working capital turnover = Revenues ÷ Working capital
= 44,556 ÷ 13,518 = 3.30
2 Click competitor name to see calculations.
The working capital turnover ratio exhibited a fluctuating pattern over the five-year period. Initial values demonstrated a generally decreasing trend, followed by a partial recovery, and then a further decline.
- Working Capital
- Working capital increased from US$6,677 million in 2021 to US$8,219 million in 2022, representing a substantial rise. This growth continued into 2023, reaching US$10,577 million. A decrease was then observed in 2024, with working capital falling to US$8,805 million. Finally, working capital increased significantly in 2025, reaching US$13,518 million.
- Revenues
- Revenues increased from US$39,211 million in 2021 to US$44,915 million in 2022. A slight decrease occurred in 2023, with revenues at US$42,857 million. Revenues remained relatively stable in 2024 at US$42,879 million, before increasing again to US$44,556 million in 2025.
- Working Capital Turnover Ratio
- The working capital turnover ratio began at 5.87 in 2021, then decreased to 5.46 in 2022. A more pronounced decline was observed in 2023, falling to 4.05. The ratio partially recovered in 2024, increasing to 4.87. However, the ratio decreased again in 2025, reaching 3.30. This indicates a diminishing efficiency in utilizing working capital to generate revenue over the period, particularly evident in the latter years.
The decrease in the working capital turnover ratio in 2023 and 2025, despite revenue fluctuations, suggests that the company is either holding a greater proportion of its resources in working capital or experiencing slower sales relative to its investment in current assets. The increase in working capital in 2025, coupled with a lower turnover ratio, warrants further investigation into the composition of working capital and the efficiency of its management.
AI Ask an analyst for more
Average Inventory Processing Period
Thermo Fisher Scientific Inc., average inventory processing period calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Inventory turnover | 4.85 | 5.06 | 5.06 | 4.60 | 3.88 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average inventory processing period1 | 75 | 72 | 72 | 79 | 94 | |
| Benchmarks (no. days) | ||||||
| Average Inventory Processing Period, Competitors2 | ||||||
| AbbVie Inc. | 99 | 90 | 73 | 75 | 65 | |
| Amgen Inc. | 189 | 199 | 411 | 281 | 231 | |
| Bristol-Myers Squibb Co. | 70 | 67 | 91 | 84 | 77 | |
| Danaher Corp. | 90 | 88 | 96 | 91 | 88 | |
| Eli Lilly & Co. | 454 | 329 | 298 | 237 | 194 | |
| Gilead Sciences Inc. | 104 | 100 | 100 | 97 | 89 | |
| Johnson & Johnson | 171 | 165 | 154 | 147 | 127 | |
| Merck & Co. Inc. | 148 | 147 | 144 | 124 | 159 | |
| Pfizer Inc. | 242 | 222 | 149 | 95 | 107 | |
| Regeneron Pharmaceuticals Inc. | 556 | 572 | 519 | 562 | 292 | |
| Vertex Pharmaceuticals Inc. | 373 | 287 | 214 | 156 | 143 | |
| Average Inventory Processing Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 164 | 149 | 143 | 119 | 117 | |
| Average Inventory Processing Period, Industry | ||||||
| Health Care | 48 | 48 | 50 | 46 | 46 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 4.85 = 75
2 Click competitor name to see calculations.
The average inventory processing period demonstrates a generally decreasing trend over the observed five-year period, followed by a slight increase in the most recent year. This indicates improving efficiency in inventory management for the majority of the period, with a potential stabilization or minor setback in the latest year.
- Average Inventory Processing Period
- In 2021, the average inventory processing period was 94 days. A consistent decline was observed in subsequent years, reaching a low of 72 days in both 2023 and 2024. This suggests a strengthening ability to convert inventory into sales more quickly. However, the period increased slightly to 75 days in 2025, potentially signaling emerging challenges in maintaining the same level of inventory efficiency.
The observed decrease in the average inventory processing period aligns with an increasing inventory turnover ratio. This correlation suggests that improvements in inventory management practices are contributing to both faster sales and reduced holding periods. The slight increase in the processing period in 2025 warrants further investigation to determine if it represents a temporary fluctuation or the beginning of a new trend.
- Inventory Turnover
- The inventory turnover ratio increased from 3.88 in 2021 to 5.06 in 2023, remaining constant in 2024, before decreasing slightly to 4.85 in 2025. This supports the conclusion that inventory is being sold and replenished more rapidly, contributing to the reduction in the average processing period. The slight decrease in turnover in 2025 mirrors the increase in the processing period, reinforcing the need for further analysis.
Overall, the trend indicates effective inventory management practices, though the most recent year’s results suggest a potential need to reassess strategies to maintain or improve upon the gains achieved in prior periods.
AI Ask an analyst for more
Average Receivable Collection Period
Thermo Fisher Scientific Inc., average receivable collection period calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | 5.01 | 5.23 | 5.21 | 5.53 | 4.92 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | 73 | 70 | 70 | 66 | 74 | |
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| AbbVie Inc. | 75 | 71 | 75 | 71 | 65 | |
| Amgen Inc. | 99 | 77 | 99 | 82 | 74 | |
| Bristol-Myers Squibb Co. | 75 | 70 | 74 | 67 | 65 | |
| Danaher Corp. | 58 | 54 | 60 | 57 | 57 | |
| Eli Lilly & Co. | 99 | 89 | 97 | 88 | 86 | |
| Gilead Sciences Inc. | 62 | 56 | 63 | 65 | 61 | |
| Johnson & Johnson | 67 | 61 | 64 | 62 | 59 | |
| Merck & Co. Inc. | 66 | 58 | 63 | 58 | 69 | |
| Pfizer Inc. | 69 | 66 | 69 | 40 | 51 | |
| Regeneron Pharmaceuticals Inc. | 146 | 160 | 158 | 160 | 137 | |
| Vertex Pharmaceuticals Inc. | 62 | 53 | 58 | 59 | 55 | |
| Average Receivable Collection Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 76 | 69 | 74 | 63 | 66 | |
| Average Receivable Collection Period, Industry | ||||||
| Health Care | 48 | 46 | 48 | 44 | 46 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.01 = 73
2 Click competitor name to see calculations.
The average receivable collection period exhibited a generally stable pattern over the five-year period, with minor fluctuations. Initial observation reveals a decrease followed by a period of consistency and a slight increase towards the end of the analyzed timeframe.
- Average Receivable Collection Period
- In 2021, the average receivable collection period was 74 days. A decrease was observed in 2022, falling to 66 days. This represents the shortest collection period within the observed timeframe.
- The period remained consistent at 70 days for both 2023 and 2024, indicating a stabilization in the company’s collection practices during these years.
- A slight increase to 73 days was noted in 2025. While this increase is minimal, it suggests a potential lengthening of the time required to collect receivables compared to the prior two years.
The observed fluctuations in the average receivable collection period are relatively small. The initial decrease could be attributed to improved collection efficiency or changes in credit terms. The subsequent stabilization suggests these improvements were sustained. The slight increase in the final year warrants monitoring to determine if it represents a developing trend or a temporary anomaly.
- Relationship to Receivables Turnover
- The receivables turnover ratio generally increased from 4.92 in 2021 to 5.53 in 2022, coinciding with the decrease in the average collection period. This inverse relationship is expected, as a higher turnover ratio indicates faster collection of receivables.
- The receivables turnover ratio then decreased slightly to 5.21 in 2023 and remained relatively stable at 5.23 in 2024, aligning with the consistent average collection period of 70 days during those years.
- A slight decrease in receivables turnover to 5.01 in 2025 accompanied the increase in the average collection period, further reinforcing the inverse relationship between these two metrics.
Overall, the company demonstrates a reasonably efficient collection of receivables. The observed trends suggest a period of improvement followed by stability, with a minor indication of potential lengthening in the final year. Continued monitoring of these ratios is recommended to assess any developing trends and maintain optimal working capital management.
AI Ask an analyst for more
Operating Cycle
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 75 | 72 | 72 | 79 | 94 | |
| Average receivable collection period | 73 | 70 | 70 | 66 | 74 | |
| Short-term Activity Ratio | ||||||
| Operating cycle1 | 148 | 142 | 142 | 145 | 168 | |
| Benchmarks | ||||||
| Operating Cycle, Competitors2 | ||||||
| AbbVie Inc. | 174 | 161 | 148 | 146 | 130 | |
| Amgen Inc. | 288 | 276 | 510 | 363 | 305 | |
| Bristol-Myers Squibb Co. | 145 | 137 | 165 | 151 | 142 | |
| Danaher Corp. | 148 | 142 | 156 | 148 | 145 | |
| Eli Lilly & Co. | 553 | 418 | 395 | 325 | 280 | |
| Gilead Sciences Inc. | 166 | 156 | 163 | 162 | 150 | |
| Johnson & Johnson | 238 | 226 | 218 | 209 | 186 | |
| Merck & Co. Inc. | 214 | 205 | 207 | 182 | 228 | |
| Pfizer Inc. | 311 | 288 | 218 | 135 | 158 | |
| Regeneron Pharmaceuticals Inc. | 702 | 732 | 677 | 722 | 429 | |
| Vertex Pharmaceuticals Inc. | 435 | 340 | 272 | 215 | 198 | |
| Operating Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 240 | 218 | 217 | 182 | 183 | |
| Operating Cycle, Industry | ||||||
| Health Care | 96 | 94 | 98 | 90 | 92 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 75 + 73 = 148
2 Click competitor name to see calculations.
The operating cycle exhibited a generally decreasing trend from 2021 to 2023, followed by stabilization and a slight increase in later periods. Analysis of the component ratios reveals the drivers behind this pattern.
- Average Inventory Processing Period
- The average inventory processing period demonstrated a consistent decline from 94 days in 2021 to 72 days in 2023. This indicates increasing efficiency in managing inventory, potentially through improved supply chain management or faster production cycles. The period remained stable at 72 days in 2024 before increasing slightly to 75 days in 2025. This recent increase warrants further investigation to determine if it represents a temporary fluctuation or a developing trend.
- Average Receivable Collection Period
- The average receivable collection period decreased from 74 days in 2021 to 66 days in 2022, suggesting improvements in collecting payments from customers. It then increased to 70 days in 2023 and remained constant through 2024, before rising to 73 days in 2025. The increase in 2025 could be attributed to changes in credit terms offered to customers, a shift in the customer base, or potential difficulties in collecting receivables.
- Operating Cycle
- The operating cycle, calculated as the sum of the average inventory processing period and the average receivable collection period, decreased from 168 days in 2021 to 142 days in 2023. This improvement suggests a shortening of the time required to convert raw materials into cash from sales. The operating cycle remained at 142 days in 2024 and increased to 148 days in 2025. The 2025 increase aligns with the simultaneous increases observed in both the inventory processing and receivable collection periods, indicating a combined effect on the overall cycle length.
Overall, the company demonstrated improved efficiency in its operating cycle between 2021 and 2023. However, the slight lengthening of the cycle in 2025, driven by increases in both inventory processing and receivable collection periods, suggests a potential need to reassess operational strategies and monitor these metrics closely in future periods.
AI Ask an analyst for more
Average Payables Payment Period
Thermo Fisher Scientific Inc., average payables payment period calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | 7.27 | 8.18 | 8.97 | 7.67 | 6.83 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | 50 | 45 | 41 | 48 | 53 | |
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| AbbVie Inc. | 72 | 64 | 66 | 61 | 60 | |
| Amgen Inc. | 72 | 54 | 69 | 90 | 77 | |
| Bristol-Myers Squibb Co. | 94 | 94 | 111 | 109 | 108 | |
| Danaher Corp. | 67 | 66 | 65 | 67 | 82 | |
| Eli Lilly & Co. | 178 | 140 | 134 | 106 | 83 | |
| Gilead Sciences Inc. | 42 | 49 | 31 | 58 | 39 | |
| Johnson & Johnson | 145 | 137 | 132 | 137 | 135 | |
| Merck & Co. Inc. | 98 | 98 | 89 | 89 | 123 | |
| Pfizer Inc. | 119 | 115 | 98 | 72 | 66 | |
| Regeneron Pharmaceuticals Inc. | 163 | 146 | 122 | 138 | 84 | |
| Vertex Pharmaceuticals Inc. | 102 | 98 | 106 | 103 | 79 | |
| Average Payables Payment Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 98 | 90 | 86 | 85 | 86 | |
| Average Payables Payment Period, Industry | ||||||
| Health Care | 59 | 60 | 61 | 63 | 63 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 7.27 = 50
2 Click competitor name to see calculations.
An examination of the short-term activity ratios reveals a fluctuating pattern in the average payables payment period between 2021 and 2025. While the payables turnover ratio demonstrates an overall increase initially, followed by a decline, the average payables payment period exhibits a more direct trend of decreasing and then increasing.
- Payables Turnover
- The payables turnover ratio increased from 6.83 in 2021 to 8.97 in 2023, indicating a more efficient use of supplier credit during this period. However, the ratio then decreased to 8.18 in 2024 and further to 7.27 in 2025, suggesting a potential slowing in the rate at which payables are being paid off in the later years. This could be due to a variety of factors, including changes in purchasing practices, supplier terms, or overall business activity.
- Average Payables Payment Period
- The average payables payment period decreased from 53 days in 2021 to a low of 41 days in 2023. This signifies an improvement in the company’s ability to manage its short-term liabilities and potentially benefit from early payment discounts. Subsequently, the period increased to 45 days in 2024 and 50 days in 2025. This reversal suggests a lengthening of the time taken to settle obligations to suppliers, potentially reflecting a shift in negotiating power towards suppliers or a deliberate strategy to conserve cash.
The observed trends suggest a period of improved efficiency in managing payables, followed by a return towards longer payment terms. The interplay between the payables turnover and the average payment period indicates a dynamic relationship with supplier credit management. Further investigation into the underlying causes of these fluctuations would be beneficial for a more comprehensive understanding.
AI Ask an analyst for more
Cash Conversion Cycle
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 75 | 72 | 72 | 79 | 94 | |
| Average receivable collection period | 73 | 70 | 70 | 66 | 74 | |
| Average payables payment period | 50 | 45 | 41 | 48 | 53 | |
| Short-term Activity Ratio | ||||||
| Cash conversion cycle1 | 98 | 97 | 101 | 97 | 115 | |
| Benchmarks | ||||||
| Cash Conversion Cycle, Competitors2 | ||||||
| AbbVie Inc. | 102 | 97 | 82 | 85 | 70 | |
| Amgen Inc. | 216 | 222 | 441 | 273 | 228 | |
| Bristol-Myers Squibb Co. | 51 | 43 | 54 | 42 | 34 | |
| Danaher Corp. | 81 | 76 | 91 | 81 | 63 | |
| Eli Lilly & Co. | 375 | 278 | 261 | 219 | 197 | |
| Gilead Sciences Inc. | 124 | 107 | 132 | 104 | 111 | |
| Johnson & Johnson | 93 | 89 | 86 | 72 | 51 | |
| Merck & Co. Inc. | 116 | 107 | 118 | 93 | 105 | |
| Pfizer Inc. | 192 | 173 | 120 | 63 | 92 | |
| Regeneron Pharmaceuticals Inc. | 539 | 586 | 555 | 584 | 345 | |
| Vertex Pharmaceuticals Inc. | 333 | 242 | 166 | 112 | 119 | |
| Cash Conversion Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 142 | 128 | 131 | 97 | 97 | |
| Cash Conversion Cycle, Industry | ||||||
| Health Care | 37 | 34 | 37 | 27 | 29 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 75 + 73 – 50 = 98
2 Click competitor name to see calculations.
An examination of short-term operating activity ratios reveals trends in the management of inventory, receivables, and payables over a five-year period. The cash conversion cycle, a key indicator of operational efficiency, demonstrates relative stability with some fluctuation.
- Average Inventory Processing Period
- The average number of days to process inventory exhibited a decreasing trend from 94 days in 2021 to 72 days in 2023. This suggests improved inventory management practices during this period. However, the processing period increased slightly to 75 days in 2025, indicating a potential slowdown in inventory turnover or a build-up of inventory levels. Overall, the period remained within a relatively narrow range between 72 and 79 days for most of the observed timeframe.
- Average Receivable Collection Period
- The average number of days to collect receivables decreased from 74 days in 2021 to 66 days in 2022, indicating improved efficiency in collecting payments from customers. The collection period then stabilized around 70 days in 2023 and 2024 before increasing to 73 days in 2025. This final increase suggests a potential lengthening of the time required to convert receivables into cash.
- Average Payables Payment Period
- The average number of days to pay suppliers decreased consistently from 53 days in 2021 to 41 days in 2023, suggesting the company was taking advantage of favorable payment terms or improving its payment processes. The payment period then increased to 45 days in 2024 and further to 50 days in 2025, potentially reflecting a shift in supplier negotiations or a deliberate strategy to extend payment terms.
- Cash Conversion Cycle
- The cash conversion cycle decreased from 115 days in 2021 to 97 days in 2022, indicating an improvement in the efficiency of converting investments in inventory and other resources into cash flows. The cycle increased to 101 days in 2023 before returning to 97 days in 2024 and increasing slightly to 98 days in 2025. The cycle remained relatively stable between 97 and 101 days for the majority of the period, suggesting consistent, though not dramatically improving, operational performance. The slight increase in 2025 warrants monitoring.
In summary, the observed trends suggest generally effective working capital management, with improvements in inventory processing and receivable collection partially offset by changes in payables payment terms. The cash conversion cycle demonstrates relative stability, although recent fluctuations merit continued attention.
AI Ask an analyst for more